The start-up also has two other clinical candidates, ERK1/2 kinase inhibitor D3S-002 and HER2×CD47 bispecific antibody D3L-000, in phase 1 development. The company has raised $250 million to date.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback